This curriculum vitae summarizes the professional experience and qualifications of Professor Pankaj Joshi. He is a physician specializing in diabetes care with over 30 years of experience. He has held academic and clinical positions in several countries and currently serves as the Director of the Diabetes Care Centre in Pretoria, South Africa. He has extensive qualifications and experience participating in clinical research trials related to diabetes treatment.

1. CURRICULUM VITAE (FEB 2010)
Name: Professor Pankaj Joshi
HPCSA NO: MP0153370
SITE / INSTITUTION DETAILS:
Institution name: Diabetes Care Centre
Postal Address: P O Box 13450, Laudium
Postal Code: 0037
Physical Address: Suite 1122 Louis Pasteur Building, 374 Schoeman St, Pretoria
Country; South Africa
Postal Code: 0001
Contact information:
Telephone no: 012-322-8271/2
Fax no: 012-320-8843
E-mail Address:prof.joshi.p@mweb.co.za
Academic and Professional Qualifications:
MB ChB University of Natal, Durban, South Africa (1972)
MRCP (UK)Royal College of Physicians, London. United Kingdom (1979)
FRS Med Royal Society of Medicine, London, United Kingdom (1981)
FICA International College of Angiology, New York, USA (1985)
FRCP Royal College of Physicians, London, United Kingdom (1993)
MACE American College of Endocrinology, Jacksonville Florida, USA (1995)
1

2. PhD Northfield University of London, United Kingdom (2002)
Date of last GCP Course: October 2007
Dispensing Licence: Yes
Relevant related work experience and current position:
1980-1981 Principal Physician Baragwanath Hospital,
Johannesburg. South Africa
1980-1990 Honorary Consultant Physician Harry’s Angels, Swaziland
Government Hospital,
Mbabane, Hlatikulu. Swaziland
1984 - 1987 Consultant Physician Kalafong Hospital, Pretoria
1987-1994 Principal Physician/Associate
Professor of Medicine
Medunsa, Head of Diabetes
Unit. Pretoria, South Africa
1994-1996 Ad Hominem Professor of Medicine Medunsa.
Pretoria, South Africa
1996 – present Emeritus ad hominem Professor of
Medicine
Director of Diabetes Care Centre
Pretoria South Africa
2009 - present Hon. Lecturer: University of Cardiff
School of Medicine, Wales, UK
University of Cardiff
Wales, UK
2

3.  Completed Advanced Scientists’ Training Course (Diabetes Research) sponsored by the EASD at
the University of Geneva, Switzerland – 1995
 Completed ‘Clinical Endocrinology 2002' at Harvard Medical School, Boston,
Massachusetts, USA
 Attendance at numerous SEMDSA, EASD, ADA, AHA, and IDF Meetings - 1984 – to date
 Appearances on Talk Shows on Radio 702, Kaya FM Radio, and TV1, TV2, M-Net, ITV on
Diabetes
 Numerous TV/Radio appearances on Diabetes & on Philosophy of Religion
 Involved in Annual Nurses Training Courses in Diabetes (Basic and Advanced) for Novo-Nordisk &
Eli Lilly since 2004
Participation in clinical trials research:
1. NESTOR Study CL36520008INT Servier (2000)
Principal Investigator
Effect of Indapamide SR on microalbuminuria - the NESTOR study (Natrilix SR versus
Enalapril Study in Type 2 diabetic hypertensives with micrOalbuminuRia)
2. NovoNorm in Clinical Practice: Marketing Surveillance Study: Novo-Nordisk (2000)
Principal Investigator
3. BioAspart 30 Insulin Study: BIAsp–1237; Phase IIIb; Novo-Nordisk (2001-2)
National Principal Investigator
A multi-national, multi-centre, randomised, open-labelled, parallel group trial to compare
glycaemic control of biphasic insulin aspart 30 in combination with pioglitazone to
biphasic insulin aspart 30 monotherapy and pioglitazone in combination with
sulphonylurea in subjects with type 2 diabetes
4. Navigator Study: CDJN608B2302; Phase III; Novartis (2002-2010)
3

4. Principal Investigator
A multinational, randomised, double-blind, placebo-controlled, forced-titration, 2x2
factorial design study of the efficacy and safety of Long term administration of natelinde
and valsarten in the prevention of diabetes and cardiovascular outcomes in subjects with
impaired glucose tolerance (IGT)
5. Glulisine Insulin Study; HMR1964/3005; Phase III; Aventis (2002-3)
Principal Investigator
Title: 26-week, multinational, multicenter, controlled, open, 1:1 randomised, parallel
clinical trial to assess non-inferiority between HMR1964 and regular human insulin
injected subcutaneously in subjects with type 2 diabetes mellitus also using NPH insulin.
6. Uprima Study: Post-marketing Surveillance Study: Abbot (2002)
Principal Investigator
7. Sildenafil in Insulin Resistance Study: A1481154; Phase II; Pfizer (2003)
Principal Investigator
A multi-centre double-blind randomised placebo-controlled parallel group study of the
safety and efficacy of oral sildenafil citrate (Viagra) as immediate-release (IR) and
modified-release (MR) formulations, given daily for the improvement with type 2 diabetes
mellitus.
8. Rosiglitazone in Combination Therapy vs. Monotherapy: 797620/004; Phase III; GSK
(2004)
Principal Investigator
A multi-centre, randomized, double-blind, parallel group trial to compare the efficacy and
safety of fixed-dose rosiglitazone/glimepiride combination therapy to glimepiride
monotherapy and rosiglitazone monotherapy in drug naïve subjects with type 2 diabetes
mellitus
9. Effect of N-5984 on visceral fat: SACT 15/2004; Phase II; Kyorin (2005)
Principal Investigator
A multicenter, phase IIa, double-blind, parallel-group, placebo-controlled study to assess
the effect of N-5984 (1mg, 3mg, or 6mg twice daily) on visceral fat and safety / tolerability
parameters, when administered orally for 12 weeks to obese patients with type 2
diabetes mellitus
4

5. 10. PEGVISOMANT TO REDUCE URINARY ALBUMIN EXCRETION IN TYPE 1 AND 2
DIABETICS: A6291015; Phase III; Pfizer (2005)
National Principal Investigator
A double-blind, proof of concept trial of the use of Pegvisomant to reduce urinary albumin
excretion in type 1and 2 diabetic patients treated with Angiotensin Convertase
Inhibitors/Angiotensin Receptor Blockers, with Persistent albuminuria.
11. TOLERABILITY OF TESAGLITAZAR THERAPTY IN TYPE 2 DIABETICS:
D6160C00003; Phase III; AstraZeneca (2005)
National Principal Investigator
A 24-week randomized, double-blind, parallel-group, Multi-centre, active-controlled
(Metformin or Metformin combined with fenofibrate) study to evaluate the Lipid Metabolic
effects, safety and tolerability of Tesaglitaza therapy in patients with Type 2 Diabetes and
low HDL-Cholesterol on a fixed background therapy with a Statin
12. EFFECT OF RIMONABANT ON GLYCAEMIC CONTROL IN TYPE 2 PATIENTS:
EFC5593; Phase III: Synofi-Aventis (2006)
Principal Investigator
A Multicenter, randomized Placebo-controlled, Double-Blind, Parallel-Group, Fixed-Dose
Study Evaluating the effect of one dose of Rimonabant on Glycaemic Control in Type 2
Diabetic Patients Inadequately controlled with Insulin
13. EFFECT ON GLYCAEMIC CONTROL AFTER ONCE DAILY ADMINISTRATION OF
LIRAGLUTIDE; Phase IIIa: Novo Nordisk (2006-2007)
Principal Investigator
A six-month randomised, double-blind, parallel-group, multi-centre, multi-national trial
with an open-label treat-to-target insulin glargine control arm
14. EFFECT of SYR-322 ON GLYCAEMIC CONTROL IN TYPE 2 DIABETICS IN
COMBINATIONS WITH INSULIN; Phase III: Takeda (2006-2007)
Principal Investigator
A Multi-centre randomised, Double-blind, Placebo-Controlled Study to Determine the
Efficacy and Safety on SYR100322 When Used n Combination with Insulin in Subjects
with Type 2 Diabetes.
15. EFFECT OF SYR-322 IN THE LONG TERM ON GLYCAEMIC CONTROL IN TYPE 2
DIABETICS; Phase III: Takeda (2006-2007)
5

6. Principal Investigator
A Multi-centre randomised, Double-blind, Placebo-Controlled Study to Determine the
Efficacy and Safety on SYR100322 When used n Combination with Insulin in Subjects
with Type 2 Diabetes.
16. EFFECT of SYR-322 ON GLYCAEMIC CONTROL IN TYPE 2 DIABETICS IN
COMBINATIONS WITH INSULIN; Phase III: Takeda (2006-2007)
Principal Investigator
A Multi-centre randomised, Double-blind, Placebo-Controlled Study to Determine the
Efficacy and Safety on SYR100322 When Used n Combination with Insulin in Subjects
with Type 2 Diabetes.
17. AWARENESS OF ABDOMINAL ADIPOSITY AS A MARKER OF CARDIOMETABOLIC
RISK; (International Prospective patient management program); RIMON_R_00704.
Principal Investigator
18. COMPARISON OF INSULIN USE AND ITS EFFECT ON GLYCEMIC CONTROL IN
PATIENTS WITH TYPE 2 DIABETES. (2007-2008)
Principal Investigator
A Phase 3, Open-Label, Parallel Group Treatment Concordance Study to Compare
Insulin Use and Its effect on Glycaemic Control in Patients with Type 2 Diabetes Mellitus:
Two Populations with Different Insulin Treatment Options.
19. SAFETY AND TOLERABILITY TRIAL COMPARING REBOXITINE. (2008-2009)
Principal Investigator.
A PHASE 2B LONG-TERM, RANDOMISED, OPEN-LABEL, SAFETY AND
TOLERABILITY TRIAL COMPARING REBOXETINE WITH ROUTINE CARE
INPATIENTS WITH CHRONIC PAINFUL DIABETIC PERIPHERAL NEUROPATHY.
20. SAFETY AND EFFICACY OF EXENATIDE IN PATIENTS WITH TYPE 2 DIABETES
USING A THIAZOLIDINEDIONE OR A THIAZOLIDINEDIONE AND METFORMIN.
(2008-2009)
Principal Investigator
A Phase 3, multicenter, double-blind, placebo-controlled, randomised, two-arm, parallel
trial designed to compare the effects of twice-daily exenatide plus oral antidiabetic (OAD)
6

7. agents and twice-daily placebo plus oral antidiabetic agents with respect to glycemic
control, as measured by HBa1c.
21. INSUMAN COMB ® 30/70 CONTROL IN THE REAL WORLD IN SOUTH AFRICA (The
ICZA Registry) (2009-2010)
Synofi-Aventis
National Coordinator
22. ANDES – AGI-1067 AS A NOVEL ANTIDIABETIC AGENT EVALUATION STUDY (2008)
Principal Investigator
A Phase III MULTICENTRE, DOUBLE BLIND, PLACEBO CONTROLLED, DOSE
FINDING PHASE 3 TRIAL COMPARING THE EFFECTS OF 2 DOSES (75mg and
150mg) OF AGI-1067 VERSUS PLACEBO ON DIABETIC CONTROL
23. PROTOCOL H80-MC-GWDC(a) SAFETY OF EXENATIDE ONCE WEEKLY IN
PATIENTS WITH TYPE 2 DIABETES MELLITUS TREATED WITH
THIAZOLIDINEDIONE ALONE OR THIAZOLIDINEDIONE IN COMBINATION WITH
METFORMIN (2008- )
Principal Investigator
Phase III multicentre, single arm, open-labelled study
24. PROTOCOL BC21713 ADD-ON TO METFORMIN, PLACEBO-CONTROLLED, HEAD-
TO-HEAD COMPARISON VERSUS SITAGLIPTIN (2009 -)
Principal Investigator
A multicentre, randomised, double-blind, double-dummy, placebo- and active-controlled
study to assess the efficacy, safety, and tolerability of taspoglutide compared to
Sitagliptin and placebo in patients with type 2 diabetes mellitus inadequately controlled
with metformin
25. PROTOCOL BC21625 TASPOGLUTIDE RO 5073031 (2009-)
Principal Investigator
A multicentre, randomised, open label, active-comparator controlled study to assess the
efficacy, safety and tolerability of taspoglutide compared to exenatide in patients with
type 2 diabetes mellitus inadequately controlled with metformin, thiazolidinedione or a
combination of both
26. SIBA TRIAL ID NN1250-3582 PROTOCOL 2008-005777-35 (2009-)
7

8. National Principal Investigator
A Phase IIIa 52-week, randomised, controlled, open-label, multicentre, multinational
treat-to-target trial comparing efficacy and safety of SIBA and insulin glargine both
administered once daily in a basal-bolus regimen with insulin aspart as mealtime insulin
+ treatment with metformin, + pioglitazone in subjects with type 2 diabetes currently
treated with insulin qualifying for intensified treatment.
Publications:
1. Van der Horst RL, Joshi P, Ahmed M, Le Roux BT, Rogers NMA, Gotsman MS. The
Chest x-ray after mitral valve replacement in childhood. S Afr Med J 1972. 46:1933-1940
2. Joshi P, Bill PLA. Duchenne’s Dystrophy associated with unusual musculoskeletal
abnormalities. S. Afr. Med. J. 1978. 54; 827-829
3. Joshi P, Kinsley R, Colsen P, Girdwood R. Ventricular Septal Defects produced by
penetrating cardiac injuries. S. Afr. Med. J. 1981. 60: 548-550
4. Joshi P, Ganda C. Electrocardiographic manifestations of penetrating cardiac injury. S Afr
Med J. 1981. 60: 955-958
5. Joshi P. Congestive Cardiomyopathy – A Review. SA J Hosp Med 1981; 7:3: 40-43
6. Joshi P, Shamley D. Unusual presentation of tuberculosis. S Afr Med J 1981; 60: 435-
438
7. Ganda C, Joshi P, Kramer S. Acute Intermittent Porphyria. S Afr Med J 1981; 60: 1789-
1792
8. Joshi P, Essop AR. Penetrating Cardiac Injuries. S Afr Med J 1983; 64: 618-620
9. Joubert PH, van der Merwe CA, Joshi P. Are we too concerned with means in the
statistical analysis of clinical research? SAMJ 1987; 72: 524
10. Joshi P. A practical approach to the diabetic patient in general family practice. Soc Disp
Fam Pract 1987; 3-5
11. Joshi P, Naran JB. A comparison of myocardial infarction in diabetic and non-diabetic
South African Indians: A 5-year study (1983-1987). Diabetes Res and Clin Prac 1988; 5:
suppl 1: 148
12. Joshi P, Joshi M. Cardiovascular Assessment in Diabetic Autonomic Neuropathy.
SEMDSA 25
th
Congress March 1989
8

9. 13. Joubert P H, Modiselle G, Dali P, Joshi P, Kalk W J. Renal Function and Glycaemic
control in black Diabetics on Home Blood Glucose Monitoring. SEMDSA 26
th
Congress.
March 1990
14. Joshi, Pontikis P, Mayeza MNT. The Prevalence Rate of Chronic Complications of
diabetes in the South African Indians – Compared to the Rates in India and Europe.
SEMDSA 26
th
Congress. March 1990
15. Joshi P, Pontikis P. Does Cigarette smoking Affect the Chronic Complications of
Diabetes? SEMDSA 26
th
Congress. March 1990
16. Pontikis P, Joshi P, Grobler P Young N C, Marshall. A Test of the Accuracy of the
Glycotronic Reflectance Meter and the use of Lenwipe in Measuring Capillary Blood
Glucose. SEMDSA 26
th
Congress March 1990
17. Joshi P, Pontikis P, Kalidas D, de Cocq D, Shah AH. Out-patient Initiation of Insulin: A
Comparison of Novopen II with Conventional Insulin Syringes. SEMDSA 27
th
Congress
May 1991
18. Pontikis P, Joshi P. Are Lipid Profiles In Type 2 Diabetics Different in Obese
Hypertensives as Compared to Non-Obese Normotensives? SEMDSA 27
th
Congress
May 1991
19. Joshi P, Pontikis P, Naran JB, Lala NP, Devchand N, Padayachy S. Prevalence of
Glucose Intolerance and Obesity in South African “Indians” living in Smaller
Communities: An Ongoing Study. SEMDSA 27
th
Congress May 1991
20. Pontikis P, Joshi P, Bhana V K. A Study of Weight Profiles in Type 2 Diabetics on
Sulphonylurea and Metformin Therapy. SEMDSA 24
th
Congress March 1988 Joshi P,
Naran J B, Adam M, Komati S. The Effect of Age on Glycosylated Haemoglobin in a
Non-Diabetic Population. SEMDSA 24
th
Congress March 1988
21. Joshi P, Joubert PH, Ebrahim SO, Mzileni O. A Comparison of the Relative Accuracy of
Two Commercially Available Reflectance Meters, Compared to the Accuracy of Visual
Assessment of Blood Glucose Estimation. SEMDSA 24
th
Congress March 1988
22. Joshi P, Ebrahim SO, Segoe C. Are Detailed Family Histories Valuable in Assessing The
Risk of Developing Type 2 Diabetes? SEMDSA 24
th
Congress March 1988
23. Joshi P. Chronic complications of diabetes mellitus. Soc Disp Fam Pract 1988; 13-15
24. Joshi P. Coronary artery disease and diabetes mellitus. CME 1991. 9: 2: 195-199
25. Joubert PH, Venter HL, Joshi P. Experience with Home Blood Glucose Monitoring in
Black Diabetics. SEMDSA 25
th
Congress March 1989
26. Joshi P, Pontikis P. Are Lipid Profiles in Type 2 Diabetics Different in Obese
Hypertensives as Compared to Non-Obese Normotensives? Cardiovascular J of
Southern Africa – 7
th
Congress of the Southern African Hypertension Society. 1991; 2: 2
9

10. 27. Joshi P, Pontikis P. What is the Effect of Insulin on Weight and Blood Pressure in the
Short Term in Diabetics with Secondary Failure on Oral Agents? Cardiovascular J of
Southern Africa – 7
th
Congress of the Southern African Hypertension Society. 1991; 2:2
28. Joshi P, Pontikis P. The Prevalence of Hypertension and Obesity in the Transvaal Indian:
An Ongoing Study. Cardiovascular Journal of Southern Africa – 7
th
Congress of the
Southern African Hypertension Society. 1991: 2: 2
29. Joshi P. Challenges of hypertension in diabetic patients. Cardiology Today 1993; 22
30. Joshi P. Numerous Challenges for Doctor with Hypertension Management in Diabetics.
Med Chron Jan 1993
31. Joshi P. Diabetes and Hypertension. Specialist Medicine, February 1995, 7; 1: 14-25
32. Guidelines for the Management of Type II Diabetes Mellitus (NIDDM) at Primary Health
Care Level in South Africa. A Consensus Document, 1996
33. Type II Diabetes Mellitus Clinical Guidelines at Primary Health Care Level (SEMDSA
Guidelines). SAMJ 87: 4; April 1997: 497-512
34. Joshi P. The physiological phases of insulin release and possible clinical implications in
management of type 2 diabetes. Journal by Fax. June 1998.
35. Joshi P, et al. In inadequately controlled patients with Type 2 diabetes, Biphasic Insulin
Aspart 30 combined with Pioglitazone provides better glycaemic control than Biphasic
Insulin Aspart 30 monotherapy or Pioglitazone/Sulphonylurea combination. IDF Paris,
France, 25 August 2003. ntv502@netvision.net.il
36. Joshi P, Joshi S. Management of Type 2 Diabetes: Treating targets and strategies. SA
Pharmaceutical Journal, September 2008. Vol. 75, No 8.
37. Joshi, et al. In Inadequately controlled patients with type 2 diabetes, Biphasic insulin
Aspart 30 combined with Pioglitazone provides better glycaemic control than Biphasic
insulin Aspart 30 monotherapy or Pioglitazone/Sulphonylurea combination. Diabetes:
2002. June 13-17; 63
rd
ADA Meeting; A453-454
38. Joshi P, Joshi S. Oral Hypoglycaemic drugs and Newer Agents use in Type 2 Diabetes
Mellitus. SA Pharmaceutical Journal, October 2008. 75: 9
39. Joshi P, Joshi S. A Review of Insulin and Insulin Regimens in Type 2 Diabetes. SA
Pharmaceutical Journal, Nov-Dec 2008. 75: 10
40. Joshi P, Joshi S. Type 2 Diabetes: Primary Health Care approach for prevention,
Diagnosis in South Africa. SA Fam Pract. 2008: 50:4: 14-20
41. Joshi P, Joshi S. Management of Type 2 Diabetes: Treating targets and strategies. SA
Family Practice, Vol. 51, No 1.
42. Joshi P, Joshi S. Oral Hypoglycaemic drugs and Newer Agents use in Type 2 Diabetes
Mellitus. SA Family Practice, Vol. 51, No 1.
10

11. 43. Joshi P, Joshi S. A Review of Insulin and Insulin Regimens in Type 2 Diabetes. SA
Family Practice, Vol. 51 No 2.
44. Joshi P, Ramjee R J. Periodontal Disease and Diabetes, South African Journal of
Diabetes, Vol. 2 No 3.
45. Joshi P. Ten Year Follow Up of UKPDS shows Glucose Lowering reduces MI, All-Cause
Mortality, Medical Chronicle, Sept 2009, p35.
TEXTBOOKS:
1. Multiple Choice Questions for the MRCP, Butterworths, London 1982, 1990:
Nominated by the Royal College (RCP) as the best seller in this category – 1994
2. Exercises in Radiological Diagnosis, Butterworths, London 1989
PRESENTATIONS & TALKS AT LOCAL & NATIONAL, &
INTERNATIONAL MEETINGS:
1. Asymptomatic myocardial ischaemia and infarction in type 2 diabetes and its relationship
to diabetic neuropathy: An exercise Electrocardiographic study. Paper presented at the
24
th
SEMDSA Congress, March 1988, Durban
2. Are side-room screening by dipstix urinalyses in diabetics of value in assessing UTIs and
presence of Nephropathy? 11
th
Academic Day, MEDUNSA, 5 September 1990
3. Does cigarette smoking affect the chronic complications of diabetes? 11
th
Academic Day,
MEDUNSA, 5 September 1990
4. The Prevalence rates of chronic complications of diabetes in the South African Indians.
11
th
Academic Day, MEDUNSA, 5 September 1990
5. A test of the accuracy of the Glycotronic reflectance meter and the use of Lenwipe in
measuring capillary blood glucose. 11
th
Academic Day, MEDUNSA, 5 September 1990
6. Asymptomatic myocardial ischaemia and infarction in type 2 diabetes and its relationship
to diabetic neuropathy and dysautonomia: An exercise electrocardiography study. 11
th
Academic Day, MEDUNSA, 5 September 1990
11

12. 7. ACE Inhibitors: Prospects for the Future. Chairman: Servier Symposium, Suppl. To
SAMJ, Somerset West, Cape, 15-17 March 1991
8. How to manage the Hypertensive Diabetic. Pretoria Medical Discussion Group Medicine
Update Symposium, Carlton Hotel, Johannesburg, 31 October 1992
9. Debate: Importance of First Phase Insulin Release. Servier, Rob Roy Hotel, Durban, 21
October 2000
10. Advances in Type 2 Diabetes Management. Conrad Hotel, Istanbul, Turkey, 23-27 May
2002
11. Amaryl in the world of Type 2 diabetes. Synofi-Aventis, Accra, Ghana, 22 August 2002
12. The Metabolic Syndrome, Insulin Resistance and Diabetes in Cardiovascular Disease.
Metabolic Syndrome Symposium. Sun City, 8 October 2002.
13. Management of type 2 diabetes mellitus: A shifting paradigm. African Health Synergies
Summit. Caesar’s Convention Centre, Johannesburg, 3 Aug 2003
14. Use of combination therapy in type 2 diabetes. Merck, Nairobi, Kenya, 18 January 2005
15. Diabetic Nephropathy. Court Classique, Pretoria, 23 February 2005
16. Diabetes Management today and in the Future. Lilly, E-doc, 19 May 2005
17. Insulin in Type 2 Diabetes. PMDG Conference, Sheraton Hotel, Pretoria, 8 March 2006
18. Use of Apidra in Clinical Practice. Apidra Launch. Sheraton Hotel, Pretoria, 11 May 2006
19. Therapeutic Approaches to Long-Term survival in patients with T2DM. Merck
Symposium, 19
th
World Diabetes Congress, Cape Town, S Africa, 4 December 2006
20. Understanding Insulin Resistance and it’s Therapy. Polmed Medical Scheme, Pretoria,
26 April 2007
21. Diabetic hypoglycaemia, hyperglycaemia and hyperosmolar non-ketotic coma. Pretoria
Medical Discussion Group. Colosseum Hotel, Pretoria, 25 June 2007
22. Understanding Insulin Resistance and it’s Therapy. Mediscor Medical Aid, Pretoria, 29
June 2007
23. Understanding Insulin Resistance and its Therapy. Medihelp Medical Aid, Pretoria, 27
July 2007
24. Beta cell dysfunction assessment techniques andDPP4 inhibitors potential. Sitagliptin
Expert Forum Meeting, MSD, Airport Sun Intercontinental Hotel, Johannesburg, 14 July
2007
25. Modern Treatment in Type 2 Diabetes. Merck, Irene Country Lodge, Pretoria, 22 Aug
2007
26. Importance and Implication of postprandial glucose excursions in diabetes management.
Eli Lilly, Lagos, Nigeria, 12 Sept 2007
27. Oral treatment modalities: Type 2 Diabetes. Novo Nordisk Diabetes Training Course,
Pretoria, 15 October 2007
12

13. 28. Global Diabetes Forum. Pfizer. Hilton Vienna, Vienna, Austria, 19-20 October 2007
29. Liraglutide Effect and Action in Diabetes. Novo Nordisk, Pan Pacific Singapore Hotel,
Singapore, 31 January 2008
30. MSD European Speaker Forum on Sitagliptin. Lisbon, Portugal, 1 March 2008
31. Chairman: Novo Nordisk Medical Ambition National Meeting. Zimbali Lodge, Kwa-Zulu
Natal, 14-16 March 2008
32. Should we treat to Target or …should we be treating to Treat to Target? CDE
Postgraduate Forum. Wild Coast Sun, Eastern Cape, 8-10 Aug 2008
33. Executive Committee member for preparing South African National Guidelines for
Diabetes Mellitus for Primary Care Physicians (SEMDSA Guidelines) 2008
34. The Management of Chronic Renal Failure. PMDG Conference, Southern Sun Hotel,
Pretoria, 20 May 2009
35. “Diabesity” – The 21
st
Century Epidemic. Novo Nordisk Zebula Lodge, Bela Bela, 20 June
2009
36. Zimbali Consensus Document: The Way Forward. . Novo Nordisk Zebula Lodge, Bela
Bela, 20 June 2009
37. Roller Coaster of Insulin Therapy in Type 2 Diabetes. Novo Nordisk Pre-CDE Diabetes
Update Symposium, Indaba Hotel, Fourways, 7 August 2009
38. JAWS III: Periodontal Disease in Diabetes. CDE Postgraduate Forum, Indaba Hotel,
Fourways, 9 August 2009
39. JAWS III: A New Risk Factor for CVD. Sanofi-Aventis Diabetes Weekend, Sun City, 14
November 2009
40. The Pathophysiology of Type 2 Diabetes, Merck Serono 1
st
International Symposium on
Integrated Approach to Disease Management: Endocrinology, Metabolic Disorders and
Cardiac Consequences: Middle East, Russia and Africa, International Conference
Centre, Cape Town, 6-7 March 2010
41. Contents or Container? – Insulin Therapy. Eli Lilly Update/Pen Launch, Vila Sterne,
Pretoria, 10March 2010
42. New Innovations in Type 2 Diabetes Therapy, Novartis Talks to Sanlam Health &
Medihelp, Pretoria, 12 June & 21 July 2010.
43. Weight of the World, Novo-Nordisk Pre CDE Symposium, Indaba Hotel, Jhb. 30 July
2010
44. Bruns-Garland Syndrome, 12
th
CDE Postgraduate Diabetes Forum, Indaba Hotel, Jhb., 1
August 2010.
45. Global Challenges, Diabetes SA National Symposium Opening Address, St George
Hotel, Pretoria, 13 August 2010
13

14. 46. Management of Type 2 Diabetes, PCNA Conference, Sandton, Novartis Sponsored, 17
February 2011
ADVISORY PANELS
Serve/d on various Pharmaceutical Advisory Panels:
• Stuart Pharmaceuticals
• Bayer Pharmaceuticals
• Chairman: Novo-Nordisk Advisory Board on Liraglutide
• Boehringer-Mannheim
• Glaxo Smith Kline Diabetes Expert Panel
• Lilly Advisory Board on Exenatide
• MSD Advisory Board on Sitagliptin
• Merck Medical Advisory Board
• Lilly for Life Achievement Award National Adjudication Panel
• Abbott Reductil Advisory Board
OTHER POSITIONS
• President: Laudium Mental Health Society
• President: Ramakrishna Institute of Spirituality & Hinduism
• Chairman of Council, Transvaal College Of Education (until closure
in 1999)
• Chairman: Board of Trustees, Shree Pretoria Hindu Seva Samaj
• Chairman: Laudium Heart Foundation
• Vice Chairman: Board of Governors, Sunrise School Foundation
• Member, SA National Religious Leaders Forum (up to 1999)
• Part-time Chaplain at SANDF
• Past Chairman - Pretoria Medical Discussion Group
• Diabetes Task Force, SA
• Exco member: Regional Committee of the Heart Foundation of
Southern Africa
• Organiser of the Laudium Heart Exhibition (1982); Diabetes
Exhibition (1983); Health Expo (1984)
14

15. • Ex-Officio member of the Crisis Centre, and Convenor of the
Symposium on Crisis Management
• Exco member: SA National Council for Mental Health
• Exco member: Standing Committee on Mental Health (SA)
• Chairman of Diabetes Symposium, Holiday Inn, Pretoria, Nov 1981
• Former Member of Rotary Club, Pretoria 6
• Executive Committee member for preparing South African National
(SEMDSA) Guidelines for Diabetes Mellitus for Primary Care
Physicians 2008
AWARDS
• Pretoria Medical Discussion Group Award for contribution to
Continuing Medical Education: 1992
• Pretoria Hindu Organisation Community Services Award: 1995
• Rabindranath Tagore Fellowship Award of the Ramakrishna Institute
of Spirituality & Hinduism: 2001
• HS Ebrahim Memorial Gold Medal for Outstanding Services to the
Pretoria Medical Discussion Group and to Diabetes Care: 2002
PROFESSIONAL MEMBERSHIPS
• Society of Endocrinology, Metabolism & Diabetes of SA – SEMDSA
• European Association for the Study of Diabetes – EASD
• International Diabetes Federation – IDF
• American Diabetes Association - ADA
• American College of Endocrinology
• National Diabetes Advisory Board, SA (up to 1996)
• SA Society of Clinical Hypnosis
• Served on Editorial Board of Diabetes Journal – “Diabetes Focus’
• Member, New York Academy of Sciences 1995
15

16. 16

17. Prof P Joshi
Student Experiences at the University of Natal Medical School:
1966 Secretary of NUSAS (Natal Medical School)
Executive Committee member of World University Services.
Executive Committee member of the Students’ Happy Valley
Clinic Committee.
1967 Fund-raising Committee Chairman of NUSAS local Comm.
1968 Medicines organiser for Happy Valley Clinic Comm.
Chairman of the Cricket Club
Chairman of the Academic Freedom Lecture Comm. of the SRC.
1969 Vice-President of the Medical Student’s Council.
Chairman/Chief Editor of the Publications Committee of the SRC
Rag Committee Chairman of the Medical Section (Natal Univ.)
Member of the Univ. of Natal Rag Funds Distribution Comm.
Member of the Disciplinary Committee.
Member of the Student’s Bursary Committee.
Leader of the Students’ Expedition to Malawi assisting in
assimilating epidemiological data working in conjunction with the
World Health Organisation.
1970 Executive member of the Students’ Representative Council (SRC)
Chairman and Chief Editor of the Students’ Publication Comm.
Presented a paper on “Malignancies of the Stomach” – A 10-Year
retrospective review “ at the Natal Medical Students Congress
Same paper also selected for presentation at the annual Association of
Medical Students’ of South Africa Congress.
Chairman of the Selection Committee for the selection of representatives
to attend the congress in Denmark at the gathering of the International
Federation of Medical Students’ Association (IFMSA)
1972 Presented Paper: The Chest X-Ray after Mitral Valve replacement at
University of Natal Students’ Medical Conference.
17

18. 18